Strategies to Overcome Multi-Drug Resistance in Cancer

dc.contributor.authorMuthiah, Divya
dc.date.accessioned2019-11-11T05:44:17Z
dc.date.issued2018
dc.description.abstractMultidrug resistance (MDR) is a common cause of chemotherapy treatment failure and can be a significant obstacle in cancer therapy. A key contributor to MDR is the overexpression of ABC transporters such as ABCB1 and ABCG2. Over the last 30 years researchers have identified three generations of inhibitors to overcome drug resistance caused by ABCB1 and ABCG2. Despite intensive efforts, a clinically usable inhibitor is yet to be identified. All three generations of inhibitors have failed due to poor cytotoxic potency, off target effects or adverse reactions. An alternative strategy to overcome MDR could be to use compounds that not only inhibit the transporter but also indirectly overcome resistance by down regulating expression of the relevant transporter through signal transduction pathways. This investigation aimed to overcome ABCB1- and ABCG2- mediated drug resistance and inhibit cancer cell proliferation using novel noscapine derivatives or the kinase inhibitor ZSTK474, in combination with existing anticancer agents such as vinblastine or mitoxantrone. It also aimed to elucidate the mechanism of action of these compounds and determine if these compounds directly or indirectly inhibited the function of ABCB1 and ABCG2. Noscapine and its derivatives were anti-proliferative in control wildtype cells (MCF7WT), and cancer cells overexpressing ABCB1 (NCI/ADRRES) or ABCG2 (MFC7FLV1000). The activity of compounds were also unaffected by the expression of ABCB1 and ABCG2. The combination of noscapine or selected noscapine derivatives with currently used anti-cancer agents potentiated anti-proliferative 11 effects in all three cell lines. Noscapine and it derivatives achieved potentiation by a) using inherent anti-cancer activity that is unaltered in the presence of ABCB1 and ABCG2 and b) increasing intracellular drug accumulation by directly inhibiting the efflux by the pump. ZSTK474 was anti-proliferative and its activity was unaffected by the ABCB1 and ABCG2 expression. The combination of ZSTK474 with anti-cancer agents in sensitive and resistant cells produced synergistic anti-proliferative effects. ZSTK474 achieved synergy by a) being unaffected by the resistance phenotype and inhibiting cancer cell proliferation, b) reducing ABCB1 and ABCG2 expression by inhibition of protein synthesis, and c) by increasing intracellular substrate accumulation via inhibition of efflux mediated by ABCB1 and ABCG2. In summary, ZSTK474 and selected noscapine derivatives overcame the resistance phenotype via multiple modes of action. The use of ZSTK474 or noscapine derivatives with anti-cancer agents used in the clinic could overcome ABCB1- or ABCG2-mediated MDR to reduce side effects for cancer patients and warrants further investigation.en_AU
dc.identifier.otherb71496543
dc.identifier.urihttp://hdl.handle.net/1885/185227
dc.language.isoen_AUen_AU
dc.provenanceThesis made OA 9.12.20 after no response from author re: extending restriction.
dc.subjectCanceren_AU
dc.subjectMulti-Drug Resistanceen_AU
dc.subjectABC Transportersen_AU
dc.subjectABCB1en_AU
dc.subjectABCG2en_AU
dc.subjectChemotherapyen_AU
dc.subjectNoscapineen_AU
dc.subjectZSTK474en_AU
dc.titleStrategies to Overcome Multi-Drug Resistance in Canceren_AU
dc.typeThesis (PhD)en_AU
dcterms.accessRightsOpen Access
dcterms.valid2019en_AU
local.contributor.affiliationResearch School of Biology, The Australian National Universityen_AU
local.contributor.authoremaildivyamuthiah@gmail.comen_AU
local.contributor.supervisorCallaghan, Richard
local.contributor.supervisorcontactrichard.callaghan@anu.edu.auen_AU
local.description.notesthe author deposited 11 Nov 2019en_AU
local.identifier.doi10.25911/5dc92b04e2515
local.mintdoiminten_AU
local.type.degreeDoctor of Philosophy (PhD)en_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Muthiah Thesis 2018.pdf
Size:
8.64 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
884 B
Format:
Item-specific license agreed upon to submission
Description:
Back to topicon-arrow-up-solid
 
APRU
IARU
 
edX
Group of Eight Member

Acknowledgement of Country

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.


Contact ANUCopyrightDisclaimerPrivacyFreedom of Information

+61 2 6125 5111 The Australian National University, Canberra

TEQSA Provider ID: PRV12002 (Australian University) CRICOS Provider Code: 00120C ABN: 52 234 063 906